Deoxycytidine
In clinical developmentAlso known as 1-(2-deoxy-.beta.-d-ribofuranosyl)cytosine, 2'-Deoxycytidine, 4-amino-1-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-2(1h)-pyrimidinone, CYTIDINE, 2'-DEOXY-+7 more
1-(2-deoxy-.beta.-d-ribofuranosyl)cytosine, 2'-Deoxycytidine, 4-amino-1-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-2(1h)-pyrimidinone, CYTIDINE, 2'-DEOXY-, DOXECITINE, Deoxyribose cytidine, Kygevvi, MT-1621 COMPONENT 2'-DEOXYCYTIDINE, dC, dCYD, 4-Amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)pyrimidin-2(1H)-one.
Recent clinical, regulatory, research and industry developments relating to this drug.
Nucleoside Therapy in Patients With Telomere Biology Disorders
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology6
- The New England journal of medicine4
- Cancer immunology research2
- International journal of molecular sciences1
- Nature communications1
- Nature medicine1
- Bhardwaj N2
- Giaccone G2
- Hammel P2
- Herbst RS2
- Punt CJ2
- Rugo HS2
- Abrams TA1
- Achkar BE1
- Cancer Center of Sun Yat-sen University2
- Department of Pathology and Laboratory Medicine2
- Harbin Medical University Cancer Hospital2
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital2
- Perlmutter Cancer Center2
- Seoul National University Hospital2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 16 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 14 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 9 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 9 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 7 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 8 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 7 of the same disease areas as Deoxycytidine in the shared literature.
Studied across 7 of the same disease areas as Deoxycytidine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials